Lead Product(s) : AUM001
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : SPRIM Global Investments
Deal Size : $27.0 million
Deal Type : Series A Financing
Details : AUM plans to use the proceeds to advance the clinical development of its portfolio with immediate initiation of two Phase II programs for MNK and TRK inhibitors including AUM001.
Product Name : AUM001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 13, 2021
Lead Product(s) : AUM001
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : SPRIM Global Investments
Deal Size : $27.0 million
Deal Type : Series A Financing
Lead Product(s) : 010DS-Zn
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Xylonix Reveals New Drug Compound for Combating Cancer and Abnormal Macrophages
Details : Xylonix demonstrated that its drug compound 010DS-Zn markedly reduced M2 population, while simultaneously boosting anti-cancer CD4 and CD8 T cells.
Product Name : 010DS-Zn
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2021
Lead Product(s) : 010DS-Zn
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable